Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
about
Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association dataCurrent concepts in diagnosis and treatment of chronic lymphocytic leukemiaRole of microRNAs in chemoresistanceProfile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemiaClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaManagement of elderly and unfit patients with chronic lymphocytic leukemia.An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessA phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Initial treatment of CLL: integrating biology and functional status.Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cellsPast, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.Obinutuzumab for the treatment of indolent lymphomaRecent advances in therapy of chronic lymphocytic leukaemia.Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia.Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia.Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile.Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations.Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemiaCanadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia
P2860
Q26738934-1A4A85FE-4A74-4B8A-9673-09B542825C19Q26770471-C28482C9-19D3-4D6B-9DB2-12A0F22BEFC7Q26770485-2D2CB60D-6873-4669-A0CB-FE6225645EDFQ26781163-D5FDD945-81C7-4ED7-B1D8-BE0547A420BFQ26783600-357B7A2F-C41D-4033-B5F4-7C832A4D6D6EQ30243914-50EB180E-7177-462C-9679-1064F2A45C18Q33709543-D08079F6-02B2-4654-BD86-837FC5401A16Q33880538-61DFBEFB-B8B2-45AB-9CE5-FD7EBD543FE2Q34172063-A6FB4350-4CB6-4CB0-A4BB-3DEE52083ECBQ34440110-84D5CF68-2F7B-4085-9637-B63AFA639D83Q34625543-BC184DBB-AB4E-429D-9C48-5CD072437298Q36219647-01F30AA3-29AC-4974-AA04-27F3183E44CAQ36305803-6DC02AC2-9689-47C8-B6F9-EBEC9D12862DQ36826893-C479FF93-1FE7-49AB-AD3D-A2BFA5E7109EQ37022297-4428484C-DE1F-4643-863C-A515E99A3A93Q38248969-10375556-9B32-431A-A896-B7239D96ED17Q38283828-9072DF5E-4200-4E6A-8B51-8497B9A6CAEFQ38397004-1C92079E-B568-4EA6-AA47-34C5EF7877BCQ38489690-D501C834-674C-4327-807C-490D04C5E788Q38530254-8F660E40-DD23-4926-859F-5CB4A2E884CDQ38601727-FDE24E84-B939-49BA-83BA-07F3CA3F0C17Q38764077-15E8B46E-DE29-43D0-B6BE-BB1766DB263EQ38818380-D901C0BE-9FB1-41E4-8C44-854CE4F6E8B4Q38862525-3C28E1F0-2E00-4D7B-89BE-5980DF2056BAQ39034465-402FC068-DE32-4AA9-A02F-F36E39279BCCQ39200835-0C106425-AA5C-4D97-B5A1-4E836BA28165Q39215476-B8E9F0DB-F0AE-42EB-AB15-D872DD15239BQ42983255-D9543719-05C2-4EE2-8614-259CE5D87014Q45252214-20B282A7-BBC8-4B02-A17F-B680BBE8C320Q46675870-645A2139-029C-416F-990F-94584F3A7D49Q47094907-385B9146-C43C-4507-9CCA-17AEC6DC3390Q47399742-AC49C20F-9828-4A02-9F98-36509B7FB6A8Q47661367-E9CBB4E5-6388-40B7-B98A-5CB01AC62620Q48751476-BA531D6D-3E82-4B29-ABC4-9F7AFA1169DAQ48870814-61C9A5B6-629E-4A71-A525-C98A965BA020Q50118863-377E114E-ACE1-4A77-9B1A-8B7EB89E67F6Q50532164-409061D0-680F-4536-9084-756C30C8252EQ50562319-D8BB8658-7A2D-4992-9D6D-D5D6155784A2Q57821050-60379F1B-83FF-49F4-B15B-6575E22D9A55Q59126180-C5AA2257-C8D5-4C4C-B25C-34E78AAD8BB3
P2860
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Chlorambucil plus rituximab wi ...... lymphocytic leukemia patients.
@en
Chlorambucil plus rituximab wi ...... lymphocytic leukemia patients.
@nl
type
label
Chlorambucil plus rituximab wi ...... lymphocytic leukemia patients.
@en
Chlorambucil plus rituximab wi ...... lymphocytic leukemia patients.
@nl
prefLabel
Chlorambucil plus rituximab wi ...... lymphocytic leukemia patients.
@en
Chlorambucil plus rituximab wi ...... lymphocytic leukemia patients.
@nl
P2093
P2860
P50
P356
P1476
Chlorambucil plus rituximab wi ...... lymphocytic leukemia patients.
@en
P2093
Achille Ambrosetti
Alessandra Alietti
Alfonso Piciocchi
Anna Guarini
Antonio Cuneo
Emanuele Cencini
Enrica Gamba
Eva Josephine Runggaldier
Felicetto Ferrara
Fortunato Morabito
P2860
P304
P356
10.1002/AJH.23668
P50
P577
2014-02-18T00:00:00Z